publication date: May. 9, 2014


Women’s Health Initiative Trial Produced $37.1 Billion in Returns

The overall economic return from the Women’s Health Initiative estrogen plus progestin trial indicates that the changes in practice it produced provided a net economic return of $37.1 billion over 10 years.

The paper, a collaboration between WHI investigators and faculty at the Hutchinson Institute for Cancer Outcomes Research, states that during the 10-year period since the main study findings were published, the changes in practice returned approximately $140 for every dollar invested in the trial. The paper was published in the Annals of Internal Medicine.

The WHI is one of the largest NIH-funded studies ever conducted on women. Housed at the Fred Hutchinson Cancer Research Center in Seattle, it is a 15-year, multimillion-dollar study established in 1991, involving more than 160,000 women throughout the U.S.

Researchers created a disease simulation model to evaluate clinical and economic outcomes for combined hormone therapy eligible women since the initial publication of the E+P trial results in 2003.

The study first estimated clinical outcomes for women taking cHT following the study versus a counterfactual scenario where the E+P trial was not conducted and cHT use persisted at historical (pre-2003) trends. Based on the projected clinical outcomes, the study then calculated the net economic return of the trial, minus the trial cost of about $260 million.

The WHI clinical trial was funded by the National Heart, Lung, and Blood Institute. Assuming that 75 percent of the change in cHT prescribing can be directly attributed to the WHI, and subtracting the cost of the study itself, the net economic return of WHI E+P trial was $37.1 billion.

During … Continue reading 40-19 Women’s Health Initiative Trial Produced $37.1 Billion in Returns

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.